Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Maintains Outperform on Icon, Raises Price Target to $285

Baird analyst Eric Coldwell maintains Icon (NASDAQ:ICLR) with a Outperform and raises the price target from $265 to $285.
byBenzinga Newsdesk
February 24, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Eric Coldwell maintains Icon (NASDAQ:ICLR) with a Outperform and raises the price target from $265 to $285.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Atea Pharmaceuticals Confirms Receipt Of Unsolicited Proposal From Tang Capital Partners’ Affiliate, Concentra Biosciences To Acquire All Outstanding Common Shares Of Atea For $5.75/Share In Cash, Plus 80% Payable From Any License Or Disposition

By Happy Mohamed
May 23, 4:13 PM
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea") confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding common shares of

AVIR